Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.

Détails

Ressource 1Télécharger: 32695101_BIB_B0551F2A3933.pdf (1259.77 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_B0551F2A3933
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.
Périodique
Frontiers in immunology
Auteur(s)
Bianchi V., Harari A., Coukos G.
ISSN
1664-3224 (Electronic)
ISSN-L
1664-3224
Statut éditorial
Publié
Date de publication
2020
Peer-reviewed
Oui
Volume
11
Pages
1215
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
Mutation-derived neoantigens are taking central stage as a determinant in eliciting effective antitumor immune responses following adoptive T-cell therapies. These mutations are patient-specific, and their targeting calls for highly personalized pipelines. The promising clinical outcomes of tumor-infiltrating lymphocyte (TIL) therapy have spurred interest in generating T-cell infusion products that have been selectively enriched in neoantigen (or autologous tumor) reactivity. The implementation of an isolation step, prior to T-cell in vitro expansion and reinfusion, may provide a way to improve the overall response rates achieved to date by adoptive T-cell therapies in metastatic cancer patients. Here we provide an overview of the main technologies [i.e., peptide major histocompatibility complex (pMHC) multimers, cytokine capture, and activation markers] to enrich infiltrating or circulating T-cells in predefined neoantigen specificities (or tumor reactivity). The unique technical and regulatory challenges faced by such highly specialized and patient-specific manufacturing T-cell platforms are also discussed.
Mots-clé
adoptive cell therapy (ACT), cancer immunotherapy, enrichment, neoantigens, tumor-infiltrating lymphocyte (TIL)
Pubmed
Open Access
Oui
Création de la notice
24/07/2020 12:45
Dernière modification de la notice
15/01/2021 7:11
Données d'usage